Management der akuten Exazerbation der chronisch-obstruktiven Lungenerkrankung (COPD)

 

 Buy Article Permissions and Reprints

Der Begriff „Exazerbation” leitet sich aus dem lateinischen „acerbus” ab und bedeutet herb, bitter, aber auch finster, unfreundlich oder heftig (Schmerz), schmerzlich. Mit „Exazerbation” wird folglich eine Verschlimmerung einer vorbestehenden Situation beschrieben. Die Exazerbation der COPD (chronic obstructive pulmonary disease) umschreibt die Eskalation einer vorliegenden Erkrankung und impliziert die Notwendigkeit einer intensiveren Betreuung des betroffenen Patienten. Die akute Exazerbation kann zu einer lebensbedrohlichen Situation mit respiratorischer Insuffizienz und hohem Mortalitätsrisiko führen.

Die vorliegende Übersicht beschreibt Ursachen, pathophysiologische Grundlagen, Prophylaxe und Therapieoptionen der COPD-Exazerbation, wobei auf die detaillierte Beschreibung intensivmedizinischer Behandlungsoptionen bewusst verzichtet wird.

Literatur

• 1 American Thoracic Society . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1995;  152 S77-S120
  Google Scholar
• 2 Anthonisen N R, Manfreda J, Warren C P W. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.  Ann Intern Med. 1987;  106 196-204
  Google Scholar
• 3 Ashutosh K, Sedat M, Fragale-Jackson J. Effects of theophylline on respiratory drive in patients with chronic obstructive pulmonary disease.  J Clin Pharmacol. 1997;  37 1100-1107
  Google Scholar
• 4 Bach P B, Brown C, Gelfand S E, MacCrory D C. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence.  Ann Intern Med. 2001;  134 600-620
  Google Scholar
• 5 Barbera J A, Roca J, Ferrer A. et al . Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease.  Eur Respir J. 1997;  10 1285-1291
  Google Scholar
• 6 Bardi G, Pierotello R, Desideri M, Valdisserri L, Bottai M, Palla A. Nasal ventilation in COPD exacerbations: early and late results of a prospective, controlled study.  Eur Respir J . 2000;  15 98-104
  Google Scholar
• 7 Barnes P J. Chronic obstructive pulmonary disease.  N Engl J Med. 2000;  343 269-280
  Google Scholar
• 8 Barr R G, Rowe B H, Camargo C A. Methyl-xanthines for exacerbations of chronic obstructive pulmonary disease.  Cochrane Database Syst Rev. 2001;  1 CD002168
  Google Scholar
• 9 Bhowmik A, Seemungal T A R, Sapsford R J, Wedzicha J A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.  Thorax. 2000;  55 114-120
  Google Scholar
• 10 British Thoracic Society . Guidelines for the management of chronic obstructive pulmonary disease.  Thorax. 1997;  52 S1-S28
  Google Scholar
• 11 British Thoracic Society Research Committee . Oral N-Acetyl cysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction.  Thorax. 1985;  40 832-835
  Google Scholar
• 12 Burge P S, Calverley P M A, Jones P W, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructiv pulmonary disease: the ISOLDE trial.  BMJ. 2000;  320 1297-1303
  Google Scholar
• 13 Calverley P M A, Pauwels R A, Vestbo J. et al . Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components in COPD (abst).  Am J Respir Crit Care Med. 2002;  165 A226
  Google Scholar
• 14 Casaburi R, Mahler D A, Jones P W. et al . A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.  Eur Respir J. 2002;  19 217-224
  Google Scholar
• 15 Celli B R, Benditt J, Albert R. Chronic obstructive pulmonary disease. London: Mosby International Ltd In: Albert R, Spiro S, Jett J (Hrsg.): Comprehensive respiratory medicine 2000: 37.1-37.24
  Google Scholar
• 16 Chodosh S, McCarty J, Farkas S. et al. The Bronchitis Study Group . Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis.  Clin Infect Dis. 1998;  27 722-729
  Google Scholar
• 17 Connors A F, Dawson N V, Tomas C, Harrell F E, Desbiens N, Fulkerson W J. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments).  Am J Respir Crit Care Med. 1996;  154 959-967
  Google Scholar
• 18 Davies L, Angus R M, Calverley P M A. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.  Lancet. 1999;  354 456-460
  Google Scholar
• 19 Dewan N A, Rafique S, Kanwar B. et al . Acute exacerbation of COPD.  Chest. 2000;  117 662-671
  Google Scholar
• 20 Eller J, Ede A, Schaberg T, Niederman M S, Mauch H, Lode H. Infective exazerbations of chronic obstructive pulmonary disease. Relation between bacteriologic etiology and lung function.  Chest. 1998;  113 1542-1548
  Google Scholar
• 21 Emerman C L, Lukens T W, Effron D. Physician estimation of FEV₁ in acute exacerbation of COPD.  Chest. 1994;  105 1709-1712
  Google Scholar
• 22 Fernandez A, Munoz J, de la Calle B. et al . Comparison of one versus two bronchodilators in ventilated COPD patients.  Intensive Care Med. 1994;  20 199-202
  Google Scholar
• 23 Garcia-Aymerich J, Barreiro E, Farrero E, Marrades R M, Morera J, Anto J M. Patients hospitalized for COPD have a high prevalence of modificable risk factors for exacerbation (EFRAM study).  Eur Respir J. 2000;  16 1037-1042
  Google Scholar
• 24 Garcia-Aymerich J, Monsó E, Marrades R M. et al . Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation.  Am J Respir Crit Care Med. 2001;  164 1002-1007
  Google Scholar
• 25 Gillissen A. Pathogenese der COPD. Bremen: Uni-Med Verlag In: Gillissen A (Hrsg.): Die chronisch-obstruktive Lungenerkrankung 2000: 46-67
  Google Scholar
• 26 Gompertz S, O’Brien C, Bayley D L, Hill S L, Stockley R A. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis.  Eur Respir J. 2001;  17 1112-1119
  Google Scholar
• 27 Jones S E, Packham S, Hebden M, Smith A P. Domiciliary nocturnal intermittent positive pressure ventilation in patients with respiratory failure due to severe COPD: long-term follow up and effect on survival.  Thorax. 1998;  53 495-498
  Google Scholar
• 28 Karg O, Bullemer F, Heindl S t. Grenzen der nichtinvasiven Maskenbeatmung bei akuten hpoxämischen Gasaustauschstörungen.  Pneumologie. 1999;  53 S95-S97
  Google Scholar
• 29 Keenan S P, Gregor J, Sibbald W J, Coon M J, Gafni A. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive.  Crit Care Med. 2000;  28 2094-2102
  Google Scholar
• 30 Mahon J L, Laupacis A, Hodder R V. et al . Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice.  Chest. 1999;  115 38-48
  Google Scholar
• 31 Moayyedi P, Congleton J, Page R L, Pearson S B, Muers M F. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.  Thorax. 1995;  50 834-837
  Google Scholar
• 32 Murata G H, Gorby M S, Kapsner C O, Chick T W, Halperin A K. A multivariate model for prediction of relapse after outpatient treatment of decompensated chronic obstructive pulmonary disease.  Arch Intern Med. 1992;  152 73-77
  Google Scholar
• 33 Nava S, Ambrosina N, Clini E. et al . Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial.  Ann Intern Med. 1998;  128 721-728
  Google Scholar
• 34 Niewoehner D E, Erbland M L, Deupree R H. et al . Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.  N Engl J Med. 1999;  340 1941-1947
  Google Scholar
• 35 Paggiaro P L, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease.  Lancet. 1998;  351 773-780
  Google Scholar
• 36 Pauwels R A, Buist A S, Calverley P M A, Jenkins C, Hurd S S. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.  Am J Respir Crit Care Med. 2001;  163 1256-1276
  Google Scholar
• 37 Plant P K, Owen J L, Elliott M W. Early use of non invasive ventilation (NIV) for acute Exazerbations of COPD on general respiratory wards: a multicenter randomized controlled trial.  Lancet. 2000;  355 1931-1935
  Google Scholar
• 38 Politiek M J, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction.  Eur Respir J. 1999;  13 988-992
  Google Scholar
• 39 Poole P J, Veale P N. The effect of sustained release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1998;  157 1877-1880
  Google Scholar
• 40 Rasmussen J B, Glennow C. Reduction in days of illness after long term treatment with N-acetyl cysteine controlled-release tablets in patients with chronic bronchitis.  Eur J Respir Dis. 1988;  1 351-355
  Google Scholar
• 41 Rodriguez-Roisin R. Pulmonary gas exchange in acute respiratory failure.  Eur J Anaesthesiol. 1994;  11 5-13
  Google Scholar
• 42 Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations.  Chest. 2000;  117 398s-401s
  Google Scholar
• 43 Rodriguez-Roisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary disease. Sheffield: European Respiratory Society In: Postma D S, Siafakas N M (Ed.): Management of chronic obstructive pulmonary disease 1998: 107-126
  Google Scholar
• 44 Rohde G, Wiethege A, Borg I. et al . Respiratory viruses in exacerbations of chronic obstructive pulmonary disease hospitalisation: a case-control study.  Thorax. 2003;  58 37-42
  Google Scholar
• 45 Sachs A P, van der Waaij D, Groenier K H, Koeter G H, Schiphuis J. Oropharyngeal flora in asthma and in chronic obstructive pulmonary disease: indigenous oropharyngeal microorganisms in outpatients with asthma or chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1993;  148 201-207
  Google Scholar
• 46 Saetta M, Di Stefano A, Turato G. et al . CD8 T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1998;  157 822-826
  Google Scholar
• 47 Schwartz J, Dockery D W. Increased mortality in philadelphia with daily air pollution concentrations.  Am Rev Respir Dis. 1992;  145 600-604
  Google Scholar
• 48 Seemungal T A R, Harper-Owen R, Bhowmik A, Jeffreis D J, Wedzicha J A. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease.  Eur Respir J. 2000;  16 677-683
  Google Scholar
• 49 Seemungal T A R, Harper-Owen R, Bhowmik A. et al . Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  164 1618-1623
  Google Scholar
• 50 Sethi S, Evans N, Grant B J B, Murphy T F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.  N Engl J Med. 2002;  347 465-471
  Google Scholar
• 51 Soler N, Torres A, Ewig S. et al . Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.  Am J Respir Crit Care Med. 1998;  157 1498-1505
  Google Scholar
• 52 Stockley R A, O’Brien C, Pye A, Hill S L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.  Chest. 2000;  117 1638-1645
  Google Scholar
• 53 Szafranski W, Ramirez A, Menga G. et al . Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.  Eur Respir J. 2003;  21 74-81
  Google Scholar
• 54 Téllez-Rojo M M, Fomieu I, Ruiz-Velasco S, Lezana M -A, Hernández-Avilla M -M. Daily respiratory mortality and PM₁₀ pollution in Mexico City: importance of considering place of death.  Eur Respir J. 2000;  16 391-396
  Google Scholar
• 55 Topeli A, Laghi F, Tobin M J. The voluntary drive to breath is not decreased in hyperkapnic patients with severe COPD.  Eur Respir J. 2001;  18 53-60
  Google Scholar
• 56 Tsai T W, Gallagher E J, Lombardi G. Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease.  Ann Emerg Med. 1993;  22 1854-1858
  Google Scholar
• 57 Turato G, Zuin R, Saetta M. Pathogenesis and pathology of COPD.  Respiration. 2001;  68 117-128
  Google Scholar
• 58 Vincken W, van Noord J A, Kesten S, Bantje Th A, Korducki L, Cornelissen P J G. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium.  Eur Respir J. 2002;  19 209-216
  Google Scholar
• 59 Voelkel N F, Tuder R. COPD exacerbation.  Chest. 2000;  117 376S-379S
  Google Scholar
• 60 Vogel F, Worth H, Adam D. et al . Rationale Therapie bakterieller Atemwegsinfektionen. Empfehlung der Paul-Ehrlich-Gesellschaft für Chemotherapie und der Deutschen Atemwegsliga.  Chemotherapie J. 2000;  9 3-23
  Google Scholar
• 61 Wollmer P, Ursing K, Midgren B, Eriksson L. Inefficiency of chest percussion in the physical therapy of chronic bronchitis.  Eur J Respir Dis. 1985;  66 233-239
  Google Scholar
• 62 Worth H, Adam D, Handrick W. et al . Prophylaxe und Therapie von bronchiale Infektionen.  Med Klin. 1997;  12 699-704
  Google Scholar

Prof. Dr. A. Gillissen

Robert Koch-Klinik, Klinikum „St. Georg”

Nikolai-Rumjanzew-Straße 100

04207 Leipzig

Phone: 0341/4231202

Fax: 0341/4231203

Email: adrian.gillissen@sanktgeorg.de